Bank Of America Corp Neu Base Therapeutics, Inc. Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.17 - $0.39 $6,440 - $14,775	37,885 Added 235.79%	53,952 $9,000
Q4 2022 Feb 10, 2023	SELL	$0.18 - $0.3 $6 - $10	-36 Reduced 0.22%	16,067 $3,000
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $452 - $1,059	-359 Reduced 2.18%	16,103 $31,000
Q4 2021 Feb 08, 2022	SELL	$2.6 - $4.18 $9,812 - $15,775	-3,774 Reduced 18.65%	16,462 $47,000
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $36,218 - $52,721	-11,076 Reduced 35.37%	20,236 $73,000

Q2 2021 Sep 13, 2021	BUY	$4.63 - $7.34 $144,974 - $229,830	31,312 New	31,312 $150,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.